SMYD3 and breast cancer: Since SMYD3 activity has been found critical in other gastrointestinal cancers, such as GC [27–29], and its genetic or pharmacological ablation has already shown to be a promising strategy to arrest BC progression [23, 30, 31], we extended the analysis of EM127 effect on chemosensitivity to GC and BC cell lines.